Olaparib – safe on normal cells, effective on cancerous cells

Olaparib – safe on normal cells, effective on cancerous cells

Olaparib 763113-22-0Olaparib is a chemotherapeutic agent that can be used in treatment of patients suffering with genetic BRCA1 and BRCA2 mutations. Recent research has shown that this drug can reduce PARP and hence, it can be used to inhibit breast, prostate or ovarian cancers.

This PARP drug has been verified at Phase I trials and Phase II tests are going on to establish efficacy of Olaparib as a cure for advanced cancers including breast cancer and stomach cancer.

This Chemotherapeutic / Anti-Neoplastic drug is available for R&D purposes from LGM Pharma. Inquire about Olaparib CAS# 763113-22-0 prices, availability, delivery, purity and more.

Usability of Olaparib

Olaparib can be used as an efficient inhibitor of Poly ADP ribose polymerase (PARP) which is an enzyme that helps in DNA repair. Patients suffering with BRCA 1 and BRCA 2 mutations may remain susceptible for certain kinds of cancers. The development of cancerous cells in such patients can be reduced by using Olaparib that inhibits PARP. This drug is also used to control cancerous cells and it can inhibit growth of tumors. Olaparib has shown effective results in patients suffering with BRCA deficient tumors and this drug is especially beneficial for patients suffering with breast and ovarian cancer. Olaparib is a biological solution for caner growth. Olaparib can kill cancer cells by blocking PAPR which is necessary for repairing DNA of cancer cells. As a result, cancerous tumor starts shrinking and it stabilizes to innocuous levels.

Olaparib Scientific Research

In 2009, during Phase I trial for Olaparib, 19 patients were administered with this drug. All patients inherited BRCA1 or BRCA2 mutations that caused advanced forms of breast, prostate or ovarian cancer. Results were positive and tumors of 12 patients were significantly reduced. One patient who was suffering with ovarian cancer was completely cured while tumors of all others were stabilized to innocuous stage. Recent research established usefulness of Olaparib as it can differentiate between normal cells and cancerous cells. Olaparib is efficient in killing cancer cells by blocking process of DNA repairing, which is necessary for development of cancer cells. It was found that Olaparib causes no harm to normal cells. Patients were able to tolerate the administration of Olaparib and no serious side effect was observed. Olaparib is going through Phase II trials and current indications suggest that this drug can be used to cure advanced ovarian, breast, prostate and colorectal tumors.

Researchers are trying to explore the biological effect of PARP inhibitor Olaparib to control and cure brain tumors, stomach cancer, pancreatic cancer and colorectal tumors.


*Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service